OR51F2

Across TCGA pan-cancer cohorts, OR51F2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OR51F2 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher OR51F2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR51F2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

ACC, SCLC, and LUSC are the cancer types where OR51F2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
SCLC	OS	Median	All	0.192	0.720	<.001	36	view →
LUSC	OS	Median	III,IV	0.095	0.691	<.001	36	view →
UCEC	DFS	Median	All	1.000	0.626	.012	30	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
SKCM	DFS	Median	III,IV	0.776	0.570	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

OR51F2–ACC (DFS)

Open the ACC breakdown →